Based on the analysis of Galecto's profitability, liquidity, and operating efficiency, Galecto is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Galecto's Other Current Assets are very stable compared to the past year. As of the 31st of January 2026, Accumulated Other Comprehensive Income is likely to grow to about 117.1 K, while Total Assets are likely to drop about 14.6 M.
The financial analysis of Galecto is a critical element in measuring its lifeblood. Investors should not minimize Galecto's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Understanding current and past Galecto Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Galecto's financial statements are interrelated, with each one affecting the others. For example, an increase in Galecto's assets may result in an increase in income on the income statement.
Galecto competes with Transcode Therapeutics, Phio Pharmaceuticals, Aprea Therapeutics, Kiora Pharmaceuticals, and In8bio. Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Galecto's current stock value. Our valuation model uses many indicators to compare Galecto value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galecto competition to find correlations between indicators driving Galecto's intrinsic value. More Info.
Galecto is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers . At this time, Galecto's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Galecto's earnings, one of the primary drivers of an investment's value.
Most indicators from Galecto's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galecto current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Today, most investors in Galecto Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Galecto's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Galecto growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Galecto help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Galecto. We use our internally-developed statistical techniques to arrive at the intrinsic value of Galecto based on widely used predictive technical indicators. In general, we focus on analyzing Galecto Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Galecto's daily price indicators and compare them against related drivers.
When determining whether Galecto offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Galecto's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Galecto Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Galecto Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Galecto diversify its offerings? Factors like these will boost the valuation of Galecto. Market participants price Galecto higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galecto data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(12.11)
Return On Assets
(0.44)
Return On Equity
(1.09)
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Galecto's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.